Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aims of this study are to investigate whether multimodal treatment of peritoneal carcinomatosis from gastric cancer is feasible and to evaluate the clinical outcomes and clinical effectiveness of neoadjuvant systemic chemotherapy followed by cytoreductive surgery + hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy, as compared to systemic chemotherapy only, in patients with peritoneal carcinomatosis from gastric cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Uppsala University
• Treatments: Camptothecin; Cisplatin; Docetaxel; Doxorubicin; Irinotecan; Oxaliplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of primary gastric cancer + histologically and/or radiologically confirmed peritoneal carcinomatosis diagnosis

• Adequate renal-, hematopoietic- and liver functions

• WHO performance status (WHO) of < 2.

Exclusion Criteria:

• Distant metastases

• Surgically not resectable lymph-node metastasis

• Contraindication to chemotherapy treatment